These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 36086553)

  • 1. Unmixing multi-spectral electrical impedance tomography (EIT) predicts clinical-standard controlled attenuation parameter (CAP) for nonalcoholic fatty liver disease classification: a feasibility study.
    Touboul A; Zouari F; Minciullo L; Modak D; Lee RMV; Wong EC; Yuen MF; Seto WK; Mak LY; Chan RW
    Annu Int Conf IEEE Eng Med Biol Soc; 2022 Jul; 2022():576-579. PubMed ID: 36086553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-Invasive Electrical Impedance Tomography for Multi-Scale Detection of Liver Fat Content.
    Luo Y; Abiri P; Zhang S; Chang CC; Kaboodrangi AH; Li R; Sahib AK; Bui A; Kumar R; Woo M; Li Z; Packard RRS; Tai YC; Hsiai TK
    Theranostics; 2018; 8(6):1636-1647. PubMed ID: 29556346
    [No Abstract]   [Full Text] [Related]  

  • 3. Electrical impedance tomography for non-invasive identification of fatty liver infiltrate in overweight individuals.
    Chang CC; Huang ZY; Shih SF; Luo Y; Ko A; Cui Q; Sumner J; Cavallero S; Das S; Gao W; Sinsheimer J; Bui A; Jacobs JP; Pajukanta P; Wu H; Tai YC; Li Z; Hsiai TK
    Sci Rep; 2021 Oct; 11(1):19859. PubMed ID: 34615918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease.
    Vuppalanchi R; Siddiqui MS; Van Natta ML; Hallinan E; Brandman D; Kowdley K; Neuschwander-Tetri BA; Loomba R; Dasarathy S; Abdelmalek M; Doo E; Tonascia JA; Kleiner DE; Sanyal AJ; Chalasani N;
    Hepatology; 2018 Jan; 67(1):134-144. PubMed ID: 28859228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.
    Siddiqui MS; Vuppalanchi R; Van Natta ML; Hallinan E; Kowdley KV; Abdelmalek M; Neuschwander-Tetri BA; Loomba R; Dasarathy S; Brandman D; Doo E; Tonascia JA; Kleiner DE; Chalasani N; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):156-163.e2. PubMed ID: 29705261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic.
    Avcu A; Kaya E; Yilmaz Y
    Turk J Gastroenterol; 2021 May; 32(5):466-472. PubMed ID: 34231477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bio-conductivity characteristics of chronic kidney disease stages examined by portable frequency-difference electrical impedance tomography.
    Yap DYH; Ma EKY; Oon WY; Lee WH; Li WH; Ho CM; Gautama B; Chan RW; Wong EC
    Annu Int Conf IEEE Eng Med Biol Soc; 2022 Jul; 2022():3378-3381. PubMed ID: 36086019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE).
    Eskridge W; Vierling JM; Gosbee W; Wan GA; Hyunh ML; Chang HE
    PLoS One; 2021; 16(11):e0260320. PubMed ID: 34847156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis.
    Semmler G; Wöran K; Scheiner B; Unger LW; Paternostro R; Stift J; Schwabl P; Bucsics T; Bauer D; Simbrunner B; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
    United European Gastroenterol J; 2020 Apr; 8(3):321-331. PubMed ID: 32213023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography.
    Tapper EB; Sengupta N; Hunink MG; Afdhal NH; Lai M
    Am J Gastroenterol; 2015 Sep; 110(9):1298-304. PubMed ID: 26303130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values.
    Petta S; Wong VW; Cammà C; Hiriart JB; Wong GL; Marra F; Vergniol J; Chan AW; Di Marco V; Merrouche W; Chan HL; Barbara M; Le-Bail B; Arena U; Craxì A; de Ledinghen V
    Hepatology; 2017 Apr; 65(4):1145-1155. PubMed ID: 27639088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Chan WK; Nik Mustapha NR; Mahadeva S
    J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY.
    Paul J; Venugopal RV; Peter L; Shetty KNK; Shetti MP
    Arq Gastroenterol; 2018; 55(1):7-13. PubMed ID: 29561981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Ultrasound Attenuation Measurement Method for the Non-invasive Evaluation of Hepatic Steatosis Using FibroScan.
    Audière S; Labourdette A; Miette V; Fournier C; Ternifi R; Boussida S; Pouletaut P; Charleux F; Bensamoun SF; Harrison SA; Sandrin L
    Ultrasound Med Biol; 2021 Nov; 47(11):3181-3195. PubMed ID: 34373137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic fatty liver disease (NAFLD) proven by transient elastography in patients with coronary heart disease.
    Mikolasevic I; Orlic L; Milic S; Lukenda V; Racki S; Stimac D; Avdovic E; Zaputovic L
    Wien Klin Wochenschr; 2014 Aug; 126(15-16):474-9. PubMed ID: 24652022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Fasting Necessary for Individuals With Nonalcoholic Fatty Liver Disease to Undergo Vibration-Controlled Transient Elastography?
    Vuppalanchi R; Weber R; Russell S; Gawrieh S; Samala N; Slaven JE; Harden L; Chalasani N
    Am J Gastroenterol; 2019 Jun; 114(6):995-997. PubMed ID: 30694869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lobe based image reconstruction in Electrical Impedance Tomography.
    Schullcke B; Gong B; Krueger-Ziolek S; Tawhai M; Adler A; Mueller-Lisse U; Moeller K
    Med Phys; 2017 Feb; 44(2):426-436. PubMed ID: 28121374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan
    Oeda S; Takahashi H; Imajo K; Seko Y; Ogawa Y; Moriguchi M; Yoneda M; Anzai K; Aishima S; Kage M; Itoh Y; Nakajima A; Eguchi Y
    J Gastroenterol; 2020 Apr; 55(4):428-440. PubMed ID: 31654131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations.
    de Lédinghen V; Vergniol J; Capdepont M; Chermak F; Hiriart JB; Cassinotto C; Merrouche W; Foucher J; Brigitte le B
    J Hepatol; 2014 May; 60(5):1026-31. PubMed ID: 24378529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.